M

Madrigal Pharmaceuticals
D

MDGL

421.50
USD
-3.42
(-0.80%)
مغلق
حجم التداول
7,046
الربح لكل سهم
-12
العائد الربحي
-
P/E
-33
حجم السوق
9,394,819,401
أصول ذات صلة الأخبار المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.